if these stocks work, we're going to be in a full-on mania. >> gigantic sell-off on what i think was news that would not warrant that. i actually bought some. >> in savannah, georgia, barbara never misses a show, celebrating her birthday. my mission is simple to make you money. i am here to level the playing field for all investors. there is always a market somewhere and i promise to help you find it. mad money starts now. hey, i am kramer and welcome in from san francisco. i am just trying to make you money. to educate and teach you. call me at 800-743-cnbc or tweet me at jim cramer.

on a day when the dow gained 359 points and the nasdaq lost, we came to the san francisco j.p. morgan healthcare conference to see the future and i liked what i saw. i did not like what i saw when i watch the joe rogan experienced this weekend. with unfettered marks and took some shots. i would say cheap shots. i mean, just terrible. it made me want to throw a yellow flag. 15 yards for unsportsmanlike conduct. and of course with the semi conductor with so much trying to accomplish. and it came out this weekend with the number of gpu purpose with 18 friendly nations. we are trying to get as many advantages as possible and i admit it is okay.

this 200 page set up rules is the hallmark of the biden administration's treating our businesses like the enemy. trying to work with all the friendly governments and not just 18. to create sovereign a.i. . he knows america can control everything and that's how powerful we are. and with other nations, he does not want to be the ugly american who dictates things the way we did during the cold war. now the government has effectively ended it by fiat. i am no fan of the chinese government, but the u.s. stays friends. this was embarrassing, shortsighted, demeaning and admittedly fitting at every turn. unless it is clean energy, of course. of course the government's are not accurate

either. i am sitting down with bristol myers and boston scientific and medtronic who have the hardest brain, heart, bone and blood- based diseases. in when the and administration target some of the biggest drugs for the so-called inflation reduction act. a lots of drug companies pray on our nation and the executives are doing their best to tackle unmet major medical needs. when i settled for chris with the ceo of bristol-myers to listen to what his company is doing for schizophrenics. there is a medicine designed to prevent strokes. and the maximum fair price does not reflect the substantial clinical value. with regards to its effectiveness reducing stroke and hospitalizations and

extended needs. this is relied upon by millions of americans daily in the most prescribed medicine on the list but not the most expensive. the ceos were persona non grata at the white house for the last four years. how could they spin $14 billion for a drug that may or may not work in diseases of the brain. the brain is hard to crack and i worry that bristol-myers is making up big mistake going for the intractable. you cannot go after the intractable without the profits from eloquence. this is what everyone else takes with money and offers nothing of real value. i would say for someone trying to develop a drug and get things going with clinical trials where most drugs fail. it is not enough that the tech and drug companies are targets of the biden administration but they are targets of each other. mark zuckerberg tried out with apple's development and nothing serious as steve jobs.

putting attacks on the app store. it is a cheap shot to say apple has done nothing since steve jobs. the highest customer satisfaction of any large-scale brand and billions of people use them. as someone who loves apple and the accoutrements, i find this self-serving and one-sided. zuckerberg said things are nonstop for the justice department. sure, apple does some things that make people have trouble leaving their ecosystem. they can make more money and users might be happier. there is truth there but apple is not stopping anyone from developing a better system. they have the app store and could can do what they want with it. there are things that apple does that i dot that method doug's that i don't like. if i were mark zuckerberg, i justice department with big tech . they have no sense. and

blasting tv media for not understanding the use of soundbites to make people look bad. i was surprised they went there and then they made it easy by crashing apple. maybe is what that is what they want to do. weird moment where the two best industries we have in the crosshairs with mark's are a zuckerberg aiding and abetting the prosecution. we heard their side of the story but tech may have been too much for everyone. and they came in and with the drug stocks that finished in the green. with the charges against these industries with just glancing blows, it was just one day when the bond market did not crash the stock. now let's go to arthur in pennsylvania. arthur. arthur? >> hey, how are you doing?

>> i'm doing well, chief, what's happening? >> i've been holding onto the shares and suck tober. it has been bullish and ince buying it has been read, nothing but read and recently more red. what is your take on amd? buy, hold or sell? >> right now amd is having trouble catching up to nvidia and frankly i have to tell you it did not get a big amazon contract. it spent a lot of money on a couple of things and right now i think it is just a hold. i wish i could say it was a buy but i don't think you can go there. let's go to rich in texas. rich. >> hey jim, how are you doing today? >> i am doing well . >> i'm all right and we have the value of united airlines with $38-$105. >> this year i am bringing you

the first source . >> no you are not and we talked about it today. i need a cohost. i am tired. rich is now my cohost. with united. he is from texas and you can't beat that either. maybe the tag team with meta-is what hurt the stock. or maybe obama crushed the stocks. these buyers are finding bargains where they can. with my time in san francisco checking on a trio. first stop, the july low for this ceo. and what a stock, it's been great, but can it keep going higher? again, read the road ahead. and trying to announce a new innovation for parkinson's. i am checking with the ceo, so stay with cramer.

>> don't miss a second of mad money follow at jim cramer at x. or you can go to cnbc.com or call us at 800-743-cnbc. miss something? go to cnbc.com. >> i want you to be a better investment and that's why we do that . >> get invested and join the club today. go to cnbc.com/join jim.

at morgan stanley, old school hard work meets bold new thinking. to help you see untapped possibilities and relentlessly work with you to make them real. after last month's massive solar flare added a 25th hour to the day, businesses are wondering "what should we do with it?" i'm thinking company wide power nap. [ employees snoring ] anything can change the world of work. from hr to payroll, adp designs for the next anything.

z's bakery is looking to add a pizza oven, arissa's hair salon wants to expand their space, and steve's t-shirt shop wants to bring on more help. with the comcast business 5-year price lock guarantee, they can think more about possibilities for their business and not the cost of their internet. it's five years of gig-speeds and advanced security. all from the company with 99.9% network reliability. get the 5-year price lock guarantee, now back for a limited time. powering five years of savings. powering possibilities™.

>> over the last six months, we have seen an incredible turnaround of bristol-myers squibb. the stocks rallied 40% from lowe's in early july. with major patent expirations but in september and new revolutionary

schizophrenia drug which has fewer side effects than anything available. there is lots of good stuff for cardiovascular disease and of course neuroscience. it is so good that we bought some bristol-myers and when we were out here for the j.p. morgan health conference we checked in with doctor chris byrne who is the chairman and ceo of bristol-myers. take a look. >> i love that you are setting the foundation for long-term sustainable growth. you have a five-year plan. >> jim, first of all it is great to be back with you. we have improved our execution on growth and we are focused on reshaping to be one of the fact just growing companies in a multiyear journey. >> i think this is possibly the

biggest drug of our generation. unmet need and huge but the standard of care is not huge. >> what we have is feedback from patients and physicians. patients are getting better without hearing voices and their getting symptom relief with cognition and able to reengage with families. we are really excited about schizophrenia but at this conference we have a string of new indications. one new string that we can use for the rest of the decade . >> and with narrow space i thought it was for major depression but in the press release they talked about schizophrenia and bipolar.

they have a drug for 2019 but i can't find a lot of people who are excited about it. did you look at the company? >> it is incredibly exciting to see the new innovations in this space. we would like to see more people focused with a huge unmet need. schizophrenia with 1,000,000 1/2 people treated with schizophrenia in the u.s. we do not have a fundamentally new mechanism of action to treat the patient's and now we do. we have efficacy and the existing atypicals but we don't see the side effects you see with those drugs and that is why we are so excited. >> did you look at the company like j&j? we look at a lot of companies and this will be a priority source. what we think about it is does

it make strategic sense for us and more importantly, we reference this earlier, can we use the science to improve the growth of the company? if i glanced over something, i apologize and when you talk about the side effect profile, i don't think you realize what has been going on and why people don't stay on it. please explain why the drugs are hated by the population that has to use them . >> what is happened for decades is patients cycle through multiple drugs until they find something that alleviates the hallucinations. they bring significant side effects like weight gain and they can't focus and that causes patients to go off of them. with the efficacy of existing therapies and you don't get the side effects . >> talk about the bipolar trial with the side effects impacting millions of people . >> a number of new indications coming with three phases this year including bipolar mania

where the existing stander of care are older and atypicals and many used off label. unfortunately, we haven't seen a fundamentally new mechanism in decades. what we like about one of the studies this year as we have three phase three studies. there is alzheimer's disease psychosis. 6 million americans are diagnosed with alzheimer's and some of those patients get psychosis symptoms. we are using cobenfy to treat them. most are treated mainly off label. >> i want to talk about what i regard as being a safe dividend that people are concerned about because you have a loss of exclusivity situation. talk about that within the context of how you got a lot of great firepower and balance

sheets. maybe it should not be a concern given your history . >> jim, our exposure is pretty well-known. we are not the first company to go through this and we have had patent losses over time. we have a plan to execute with three components of the plan. first we have a young portfolio for growing assets. good momentum this year with a string of catalysts having data coming out over the next 18 to 24 months. we have the strong financial position which gives us the ability to give money back to shareholders with an attractive dividend over the years. >> let's talk about the rest of the growth port folio. let's talk about oncology. people say you are done, are you done? we are not done with an exciting suite of opportunities including oncology. we are a leader today and immuno oncology with good progress extending that business potentially into the next decade. we have added to our position

in targeted therapies and we have platforms with cell therapy and oncology that will generate opportunities. last year, we bought into one of the fastest growing platforms in oncology wishes radiopharmaceuticals. we are maintaining our leadership. >> that is novel, how do you feel about it? >> we feel very good about it. after i became ceo in 2023, we see the first data coming out from the plat form in a couple of years with our platform. this could be an opportunity, potentially in the future to replace chemotherapy . >> what about eloquence? >> cardiovascular care is where we have been a leader for a long time and eloquence is an important drug for us today. about 40% of patients cannot benefit and we have an opportunity with our drug which

is a factor 11 drug. one of the products over the next years to address that with a-fib, we have two other studies running in parallel . >> i want to circle back because we have done a lot of work with brain. if you are someone or a parent of someone with schizophrenia, talk about how they can get into the trial. the fda is so in favor of this that they put out the release ahead of you . >> we have a great opportunity with schizophrenia and we have an ongoing schizophrenia study coming out this year with combined use. you can go talk to your physician or look at clinical trials online with tremendous opportunity for many patients and that is one of the many things we are working on to transform this company to deliver top growth. >> it is important for every city in america .

>> one of the things we love is the real opportunity with this medicine to change the narrative around this disease. >> thank you, just so people will know, i doubted you. no one can solve the brain . >> that is what we do at bristol myers squibb . >> thank you christopher boerner, ceo . coming up, can boston scientific keep it going and after 2024. he sits down with the company's ceo, next.

check in time is 3:00 it's 2:55. i know. is this what he's doing now? as your host, i have some rules. first, no showers longer than 5 minutes. this isn't a spa. no games. no fun. yes, coach. (♪♪) meanwhile, at a vrbo... when other vacation rentals make you share your turf with a host, try one you have all to yourself. your loved ones are getting older, and they need your support. care.com is here to help. it's an easy way to find background-checked senior caregivers in your area. and some piece of mind. see why millions of families have trusted care. go to care.com now

(auctioneer) let's start the bidding at 5 million dollars. (man) robinhood gold members get a 3% ira match.sted care. while the wealthy hoard their perks, our retirement contributions are boosted by 3%.

now with robinhood gold. new projects means new project managers. you need to hire. i need indeed. indeed you do. when you sponsor a job on indeed, it's easier for talented candidates to find it. which makes it easier for you to hire them. visit indeed.com/hire i had the worst dream last night. you were in a car crash and the kids and i were on our own. that's awful, hon. my brother was saying he got life insurance from ethos. and he got $2 million in coverage, all online. life insurance made easy. check your price today at ethos.com.

we are here in san francisco for the healthcare conference. and who is coming at it with more momentum than boston scientific best known for its cardiology franchise . they also have a big medical surgical business from endoscopic to urology. they are up 55% largely thanks to its new ablation system for arterial fibrillation. it's also known as a-fib. the stocks are up another 6% thanks to j&j which launched a

competing product months after its approval with four reports of strokes, serious stuff. the reports of a-fib and this company is about more than one product with her great portfolio and can generate double-digit business. don't take it from me, we got a chance to talk to boston scientific who is the chairman and ceo. take a look . >> what can i say? you are on a roll. i think you are in the best shape of any of the companies i am speaking with today. talk to us about what you are doing and you have a new application. >> first of all, we are coming off of an excellent 2023 or a better 2024 and we aim for a terrific 2025 and beyond with talent across our company. the key is we have eight businesses and almost all are growing faster than the market. we have two breakthrough

products transforming healthcare. one is driving the growth of the company. >> talk about what it means to have the kind of marketshare you have. and also for something to happen just last week with j&j. >> so, the treatment of a-fib with 40 million patients that suffer from a-fib. if you have a-fib, your heart beats it irregularly and it can cause heart failure and possibly stroke. we have transformed this market . it will be our largest business in 2025. we've gone from the number of four player to number two and 2025 and we are aiming for number one shortly thereafter. why it is so great for hospitals and physicians and ultimately patience is it is a safer procedure. people who are younger or those who are older with comorbidities , it is a safe procedure and very epic as a epic cases with

200,000. hospitals love them because it is faster and patients get in and out of the hospital faster and reduce the risk of stroke and heart failure. >> this sounds like something that people are worried about and concerned about with vaccines and it will not impact your business. to me, you would be one of the few i would regard as safe in this new administration . >> with med tech in general, we don't have tremendous pricing power and we typically have flat pricing and we deliver products with an excellent safety track record and are beneficial to patients. >> we've got to talk about it reducing the risk of stroke. this is the big fear people don't know about it until they hear it. they think it is boilerplate and it isn't . >> it is an existing market that we are transforming. it is an over $2 billion market

this year and will grow to over $6 billion based on clinical trials. so watchmen if you have a-fib and if you get treated to picture a-fib, what it will do is further reduce your risk of stroke and allow patients to get off of blood thinners. to go and live a normal and active life without the risk of bleeding that so many people have . >> you have to understand that in and older person, it is fearful they may fall because they could be anywhere and bleed out quickly. >> my mother just received a watchman device . she wanted to reduce the risk of stroke and she wanted to walk her dog. she wanted to walk her dog in winter and reduce the risk of falling. the procedure takes less than one hour and you are out of the hospital in the same day . >> one thing you do well that

others don't -- others are spending billions on new drugs but don't have the pipeline. you had the foresight to be involved with watchman very early . >> we think about innovation all the time and it is key for our business and we are positioned in the company to be great for the next 10 years. one of the things we do besides her chronic r&d as we are and meditate. this year and a fest 2024. we had 25 companies that are early- stage companies. historically, we have acquired one third of those companies from our venture portfolio to drive beyond what we do with interventional r&d. we have eight divisions with the largest endoscopy company in the world and we just acquired a company to treat overactive bladder. we have an large neuromodulation

and there are eight divisions. most all of them going well above their peer group . >> what should be we be watching next? talk about some of these others. people feel that right now you are watchman and not much else . >> there is procedure to do both at the same time . >> how many doctors know how to do that . >> almost all electrophysiologist and interventional cardiologists are doing that. we have a drug for the coronaries. and another called intravascular ultrasound . >> talk about that. i thought it was really exciting and it's pretty invasive without that . >> we have the widest portfolio to treat coronary artery every disease, the plumbing of the

heart. this will break up calcium to prepare a student procedure. you want to see the artery and prepare and treat the artery at the same time. we are able to to use the imaging and then treat the artery. >> frankly, i thought it was science fiction. i'm not kidding, it is laser based and kind of crazy . >> essentially it is a balloon. you image the heart first and then put a balloon where there is a need for a stent and the lasers actually break up the calcium within the vessel. so you prepare the vessel for a stent and then the stent will do its job perfectly . >> i've got to tell you that people don't realize how hard the things are that you are doing. some of these are just fatalities and you have taken this off the table and congratulations for all you are doing. by the way, the best-performing

of all of the companies we are going to see with maybe the exception of eli lilly. thank you so much . >> thank you. coming up, could a new treatment for parkinson's beyond the verizon.? investment opportunities are everywhere you turn. do you charge forward? freeze in your tracks? or, let curiosity light the way. at t. rowe price, we ask smart questions about opportunities like advances in healthcare and how these innovations will create a healthier world tomorrow. better questions. better outcomes.

♪♪ only servicenow connects every corner of your business, putting ai to work for people. pfft ... every corner? every corner, nick. ow! so kate in hr ... hey kate. can focus on people, not process. patty in it is using ai agents to deal with the small stuff, so she can work on the big stuff. and ai helps jim solve customer problems before they're problems. oh, so we all work better, together! my work here is done. excuse me, which way back? the great barrier reef. huh? here we are. oooh. — g'day. — uh, where am i? australia! and you look like you need a vacation. show us what ya got. (♪♪) remarkable. yep! it's amazing. i love it! — what is it? — a wombat. come on! (♪♪) jump! down under, g'day is the start of every good adventure. so, what are you waiting for? come and say g'day. (♪♪)

i guess what i'm looking for from you is, i mean, i know how the fire affected me, and there's always a constant fear that who's to say something like that won't happen again? that's fair. we committed to underground, 10,000 miles of electric line. you look back at where we were 10 years ago and we are in a completely different place today, and it's because of how we need to care for our communities and our customers. i hope that's true. [joe] that's my commitment. [ambient noise] it is cold out here in san francisco for the j.p. morgan health conference. we had a chance to catch up with medtronic with neuroscience and diabetes .

this company has had a bunch of successful product launches and after the selloff in recent months, it's not chief. i sat down with the chairman and ceo of medtronic , geoff martha . take a look . >> you have so many things going on but something right now you want to tell me about . >> we are super excited to be here with all the information we have coming in in the late breaking news we nnounced today has to do something that is near and dear to your heart which is for parkinson's. we just got approval in europe and other countries for adaptive dvs. we can send signals in the brain and we have the algorithm for real-time adjustments to the therapy automatic the. that just got approved . >> with millions of people with hope .

>> yeah . >> you are actually a pioneer in this field . >> yep . >> how does this change things? first fall, parkinson's gets worse over time, right? >> the therapy we provide gets updated episodically where the patient goes in to the physician along with the electronics to update the therapy for wherever the patient is. now it happens real-time every day with this adapter. it's better for the patient and better for the healthcare system because it is a lower burden. i think that the physicians will prescribe it more because it is less of a burden on the healthcare system. >> people don't go after parkinson's because of the failure rate . >> right. but you have a way to deal with it like you do hypertension. i hope the government will pay because there is the need for

hypertension. >> is the number one contributor to death in the world. 50% of cardiovascular disease and stroke related debt is caused by hypertension. 75% of people with hypertension do not have it under control and stop take their medicines. we got a new approval from the fda and since then we've been putting the reimbursement puzzle pieces in place. on january 1 them, it's an outpatient procedure . >> it's incredible and it is invasive singing >> the patient's, we are finding great response from patients with mild anesthesia and you wake up and you don't know what happened. you don't feel pain in your blood pressure goes down. we just got this outpatient procedure approved and that's going into effect january 1.

the last piece of the puzzle is who will be covered. we are working with cms in the u.s. government as well as commercial payers. once we get that piece snapped in, this is going to scale . >> i think people don't realize that folks stop because they don't know they have anything wrong . >> right, it's a silent killer . >> and you are doing paying too . >> it comes back to this sensing technology in the brain. and the spinal cord as well. sensing pain signals and adjusting therapy. with the spinal cord 50 times per second to identify the pain because pain is hard to quantify. you are familiar with nature, one of the leading clinical publications. and we just had the marker approval and this is a computer- based device. it is classified as bci and we

have 40,000 people with this technology alone. it is force of magnitude with the largest pci device out there . >> you are working on something i don't know that is about to be approved, what else is in the pipeline here? >> i would say it is a-fib. a-fib is a huge problem as people get older and start to outlive their hearts. >> with j&j, it looks like they are in trouble . >> i would say j&j is the incumbent with the previous technology which worked fairly well. this new technology that boston scientific and medtronic are advancing is a step forward. boston got there first and they have big market share but we have a more comprehensive port folio and we believe our latest technology is the highest for

physicians and we are scaling that now . >> you are willing to take on diabetes in a way no one else is. congratulations to you. >> look, technology, one of the problems with healthcare in the industry as we come out with solutions that work in a niche way. you need to work on broader solutions and for us that means working with other companies. we have worked with space x even outside of our industry. inside our industry, we just announced a partnership with siemens to help with our surgical business and recently abbott, who is a competitor. and with the covid epidemic, you shared knowledge. he was extremely knowledgeable. this was a valve we had trouble procuring for ventilators and it just so happened that space

x was making the valve for their space craft for the life- support systems . >> i have to tell you as we go over all the things you are working on. i'm talking about ablation and cardio and diabetes. the one thing i don't understand is $80 for a company with consistent mid digit and high single growth. i don't get it. i don't get what your stock is doing today . >> look, we control what we can control. we are driving innovation and the financial that we are shooting for is the very least mid-single digit revenue growth and then translating that to leverage the p&l. in this back half we will have high single digit and then added dividend on top of that you get a high double-digit. i think

the stock will take care of itself . >> i got to go for the colonoscopy. i have asked for your a.i., will i get it? >> it is standard of care we can easily get that to you . >> was 18% the last i talked to you and apparently the number is much higher . >> the big gastroenterology practices realize they are missing . >> i understand why the profession itself is not up to what you guys are doing. i want to think you, geoff martha, the ceo of medtronic . >> thank you. >> coming up, cramer takes your call in the sky is the limit in a fast fire lightning round, next. the average dog only lives to be ten. that's ten birthdays, ten first summer swims, ten annual camping trips.

at the farmer's dog, we don't think that's long enough. that's why our freshly made food comes pre-portioned just for your dog. because a dog at a healthy weight could live a longer, happier life. [dog barks] ♪♪ this is clem. clem's not a morning person. or a night person. or a...people person. but he is an "i can solve this in 4 different ways" person. and that person... is impossible to replace. you need clem. clem needs benefits. work with principal so we can help you help clem with a retirement and benefits plan that's right for him. let our expertise round out yours.

you founded your kayak company because you love the ocean. not spreadsheets... you need to hire. i need indeed. indeed you do. our matching platform lets you spend less time searching and more time connecting with candidates. visit indeed.com/hire

>> lightning round is sponsored by charles schwab, trade brilliantly. >> it is time. for buy or sell. then the lightning round is over. are you ready? let's go to brad. brad . >> jim, what's going on with this stock? what is happening? >> what is happening? that is the worst collection i have seen and i think those guys should continue to go lower and living up to their expectations. let's go to jersey in new jersey, jersey . >> how are you? >> i am great, how are you? >> thank you for the leadership . >> you are very kind. >> i am right over here by

woodland park. so, my question is all about manifestation. it just makes sense with ralph lauren, what is the power behind ralph lauren? >> first of all, i will tell you what the power is behind it. it is literally for 15 years and it still looks terrific. i like the blue label and the purple label and i think you have a winner there. now is go to anthony in florida. anthony . >> k jim, i am a big fan of opera. i think the company is trading at a cheap price relative to value and i would love to hear your thoughts . >> i used to go to the opera and i like carmen and a lot of the german operas but i don't know about this opera. you have stumped me. i will do some work on it. i will go with

my chief scientist to find out what is going on there. let's go to tom in new york. tom . >> and i'm a lifelong suffering jets fan here . >> i wish i could help you. the new coach from the cowboys might be your man . >> let's go, i'm ready. >> i'm sorry. i'm a huge believer in aspen air and they have signed some super big contracts for 2024 with hopefully more to come. give me the green light, i want to load up . >> it may be good and you need the fed to cut rate 17 times for that to happen. maybe 42 tops. i would be slow in buying. let's go to jacob in my home state of pennsylvania. jacob . >> thanks for having me on .

>> absolutely. i want to ask your opinion on a bus. >> it is a three dollars stock and it loses money. you could go to the casino and play it with a series of tight ends for the eagles or you can buy buttress. take your pick . >> how about jacob in alaska. jacob . >> k jim, thank you for taking my call and for all you and your team to paradigm a first time caller here. >> as a frequent flyer, i have a lot of experience with different airlines and discussions in the sector and i know where you stand with delta and united. what are your thoughts on the longer-term carrier, alaska airlines? >> they are so good and this is their moment and i think you have a winner, i would stick with it. let's go to henry in new york. henry .

>> hey professor cramer, thank you for sharing your knowledge with our home gamers . >> thank you. what's going on? >> i am looking at a specific stock to my portfolio and i'm looking at katie are but want your perspective . >> with this be henry kravitz calling from new york. i'm going to bed it's not henry kravitz but i will say i like the stock very much. >> that made no sense to me whatsoever. now to walter. walter. >> it is great to talk to you from the garden state, i'm with you . >> i love the garden state and i'm all over it, what's going on . >> i'm in a conundrum. i've always thought of myself as a fairly intelligent guy and last year on your show, a money manager recommended and it was

113 and has dropped 25%. why come i don't know. with $7 million not going to with chatgpt. >> the one thing i would say and i hasn't haven't had a money manager on this show for 20 years. and i haven't done that for ages . i would say don't look at me but stick with cramer. >> the lightning round is sponsored by charles schwab. or with the best full-service wealth management skills in the biz. tech asst: actually i'm seeing something from schwab. (uh-oh) producer : yeah, schwab lets you invest and trade on your own. and if you want they can even manage it for you. not to mention, schwab has a team of specialists for taxes, insurance, and estate planning. both producers: all with low fees. carl: we're experiencing technical difficulties... uh, carl... schwab! schwab.

a modern approach to wealth management.

>> the game of vacation of the quantum computer is finally wrapping up and all it took was a one-two punch. it met its mark to knock him to the canvas. in the widest that i've seen in

ages. saying, i'm not an expert in quantum computing but my understanding is it a ways off from being a practical paradigm . very similar to what we heard when it was said it could be 20 or 30 years before we are using wanting computing. i am glad they popped the bubble because quantum computing companies are money losers. take getty computing, please. the company sold 50 million shares at two dollars and traded $20 million and plunged back to $6 million. what is really going on? there is a game going on with nothing to do with quantum computing. the gamers come in early between 4:00 and 6:00 a.m. and they buy and buy some more. the short thing is easy money.

let's say the stocks trade at 30 and then they take to 31 and 32 and 33 and higher. they can cover the opening and make a few bucks. then excited latecomers coming in paying 34 and 35 and 36. the early-morning borrowers panic and then cover. this time one wrecked everything by simply telling the truth as they know it about quantum computing which is it isn't going to be commercially viable until the 90s. with nuclear reactors are clean energy, the fact is they never had anything to do with science but were to nail the short- sellers. i want this bloods port game nipped in the bud. we don't want top 11 which is why i was glad when the quantum computing bubble popped. there is so many things going wrong right now with tariffs and taxes and

inflation. i can deal with those but i cannot deal with the unsustainable greed. with the speculative companies, they don't want to be stupid. the fact is that insiders jump on it and that's what happened during the collapse in 2002 when a lot of companies sold their stocks only to be crushed by secondary insider selling. then the worst bear market in years. i am worried there will be worse after the total quantum balloon. it is not too late to sell, given where these came from. i hope it will be a lesson and that the game stock era is over. go to fan dual if you want to gamble. these people are putting on a 14 parlay with quantum computing. to which i say, good luck, but it makes mo to draftkings. and

just like the one they are suffering now. here is your hat and what's your hurry? don't let the door hit you on the way out. and you can be here on mad money. i am jim cramer i will see you tomorrow from san francisco. force, there thinking did i hear you're a royalty business? very similar to a royalty business. yippee-i-o-ki-yay. [ laughter ] you are drowning in opportunity. what have you sold? $56. our biggest obstacle is capital. ooh, that's a bad idea. that sucks. i don't trust you with my money. i'll give you $400,000. mark, are you in or out? $75 million. whoa! it's the american dream. -- captions by vitac -- ♪♪ narrator: first in the tank is a product to help kids sleep more soundly.